Canada’s agreement with COVID-19 vaccine manufacturer Novavax has been released in regulatory filings, showing the drug maker has set delivery schedules, but also has broad leeway to miss them for a variety of reasons.
All of Canada’s seven vaccine contracts have been kept confidential since they were signed last year and the government has fought moves in parliament to force the disclosure of the contracts. The released contract is still heavily redacted, with all the details on price, deliveries and penalties for missed timelines for Novavax blacked out.
The contract, filed with the U.S Securities and Exchange Commission on Monday, does specifically acknowledge there are many problems that could prevent the company from making its deliveries on time.
“Customer acknowledges that the delivery schedule may change due to several variables. Including but not limited to speed of clinical trial enrolment and accrual of events, manufacturing delays and/or timing of regulatory approval,” reads the contract. It also specifies the delivery schedule is an “estimate only.”
No comments:
Post a Comment